DTR 2023 HOME

Year-One Success Stories

The Navitus difference is something clients see within the first year. We consistently receive feedback that unmatched data access, our 100% pass-through model and our people-first approach produces positive change compared to experiences with a previous PBM.

We serve a wide spectrum of commercial clients including public and private employers, health systems, public service entities, and school districts.

Across these market segments, clients realized significant negative trends in per member per month (PMPM) costs within the first year with Navitus. Navitus delivered cost-savings by eliminating spread pricing, reducing waste and providing a 100% pass-through approach on rebates.

1-year chart-01-Jun-24-2024-09-44-37-5023-PM

¹Totals weighted with consideration of average member lives across these organizations

Methodology

The Navitus drug trend is calculated by comparing the net total cost PMPM for 2023 to that for 2022. Net cost PMPM represents full-year (Q1-Q4) data for total member copays and plan paid amounts minus manufacturer rebates and fees. This value is divided by the total number of members and by 12 months of the year.

Net total cost PMPM trend consists of two components: utilization and cost and includes both specialty and non-specialty drugs. Utilization trend measures the change in total days of therapy. Cost trend measures the change in net total drug cost per the above. This analysis included data for more than 500 clients, representing 3M members within Navitus’ commercial book of business, including plan sponsors and health plans. To be included, these organizations must have been clients of Navitus in both 2022 and 2023. Exclusions from this analysis include products administered at physicians’ offices, clinics and hospitals, COVID-19 vaccines and supplies, weight loss products and any additional savings from copay assistance programs.